OPEN ACCESS

Scholars International Journal of Traditional and Complementary Medicine

Abbreviated Key Title: Sch Int J Tradit Complement Med
ISSN 2616-8634 (Print) | ISSN 2617-3891 (Online)
Scholars Middle East Publishers, Dubai, United Arab Emirates
Journal homepage: https://saudijournals.com

Review Article

Meta-Analysis of Transfection

Sharique Ahmad[1*], Priyesh Srivastava[2], Mohd. Ibrahim[3], Beenish Bano[4], Mehnaz Khan[5], Faraz Shamim[6]

[1-6]Department of Pathology, Era's Lucknow Medical College and Hospital, Era University, Lucknow

DOI: https://doi.org10.36348/sijtcm.2025.v08i01.003 | **Received:** 13.12.2024 | **Accepted:** 17.01.2025 | **Published:** 24.01.2025

***Corresponding author:** Sharique Ahmad
Department of Pathology, Era's Lucknow Medical College and Hospital, Era University, Lucknow

Abstract

Transfection is a critical technique for introducing nucleic acids—such as DNA, RNA, or oligonucleotides—into cells and plays a pivotal role in diverse research fields, including gene therapy, recombinant protein production, and functional genomics. This meta-analysis examines the fundamental mechanisms, methodologies, and challenges associated with transfection, highlighting advances in both viral and non-viral delivery systems, optimization techniques, and clinical applications. Viral vectors, including adenovirus, retrovirus, and lentivirus, offer high efficiency and are frequently used in gene therapy applications, while non-viral methods, such as lipid-mediated transfection, polyethylenimine (PEI), dendrimer complexes, electroporation, microinjection, and biolistic delivery, provide safer alternatives but often exhibit lower efficiency, necessitating optimization. Lipid-based transfection remains one of the most widely used methods, particularly lipofection, due to its ease of use and efficiency in commonly used cell lines like HEK293 and HeLa cells. Electroporation is effective for challenging cell types, such as primary neurons and stem cells, though high cell mortality rates necessitate careful optimization. Transfection has significantly contributed to gene therapy, particularly for genetic disorders such as cystic fibrosis, hemophilia, and spinal muscular atrophy, with viral vectors employed in CAR-T cell therapy for cancer treatment showing promising results in hematological malignancies. Recent advances in mRNA transfection have revolutionized vaccine development, exemplified by mRNA vaccines for COVID-19, demonstrating the potential for further therapeutic applications. However, challenges remain, including achieving high transfection efficiency while maintaining cell viability, especially in primary cells and stem cells, which are more resistant to transfection than immortalized cell lines. Cytotoxicity and off-target effects limit the clinical utility of transfection, particularly in gene therapy, where insertional mutagenesis poses significant safety risks. The cost of scaling transfection for therapeutic applications, such as CAR-T cell production, remains prohibitive. Future research will focus on overcoming these limitations while advancing the clinical applications of transfection for therapeutic gene delivery and personalized medicine. Overall, as new materials, technologies, and optimization strategies are developed, the efficacy, safety, and applicability of transfection techniques will likely improve, enhancing their role as cornerstones of molecular biology and biotechnology.

Keywords: Transfection, Nucleic Acid, Gene Therapy, Functional Genomics, Molecular Biology, Biotechnology.

INTRODUCTION

Transfection is a fundamental tool in molecular biology, used for introducing foreign nucleic acids into eukaryotic cells. It enables researchers to study gene function, manipulate gene expression, and produce recombinant proteins. This technique has become a cornerstone in genetic engineering, synthetic biology, and therapeutic development. Its widespread use spans basic research to clinical applications, including immunology, oncology, and stem cell therapies.

Transfection methods have significantly evolved since their inception, leading to the development of various techniques. These methods can be broadly classified into chemical, physical, and viral strategies, each with distinct benefits and limitations. This meta-analysis explores the efficiency of different transfection methods, focusing on their use in research and clinical settings. It also delves into the technological advancements aimed at improving these processes and overcoming the associated challenges.

Mechanisms of Transfection

A) Chemical-Based Transfection

Chemical methods of transfection have gained popularity due to their simplicity and adaptability. The two most common approaches—lipid-based and polymer-based—facilitate cellular uptake through the endocytosis of nucleic acid complexes.

Lipid-Based Transfection: Liposomes, artificial vesicles composed of phospholipid bilayers, are commonly used to encapsulate and deliver nucleic acids. These lipid-nucleic acid complexes merge with the cell membrane, allowing entry into the cytoplasm. Commercial reagents like Lipofectamine are widely used in many research settings, particularly for adherent cell lines like HEK293 and HeLa cells [1]. However, primary or suspension cells often present lower transfection efficiencies with this method.

Polymer-Based Transfection: Polymers such as polyethyleneimine (PEI) and dendrimers bind with nucleic acids to form nanoparticles that are easily taken up by cells. PEI has been extensively studied for its ability to condense DNA and facilitate cellular uptake, making it a reliable option for gene delivery in specific settings [2]. Dendrimers, highly branched polymer structures, offer enhanced transfection efficiency in some cell types, though concerns about their toxicity remain [3].

While these chemical methods are efficient for in vitro studies, their use in vivo is limited due to challenges such as serum-induced degradation and potential toxicity.

B) Physical-Based Transfection

Physical techniques involve temporarily disrupting the cell membrane using mechanical or electrical forces to allow the entry of nucleic acids. Although highly efficient, these methods may increase the risk of cell damage.

- Electroporation: This method involves applying an electrical field to cells, temporarily permeabilizing the cell membrane and facilitating the entry of nucleic acids. It is especially useful for transfecting challenging cell types such as primary neurons and hematopoietic stem cells [4]. However, electroporation can cause significant cell mortality due to membrane disruption [5].
- Microinjection: Microinjection is a precise technique where nucleic acids are directly introduced into the cytoplasm or nucleus of a cell using a fine needle. Though highly accurate, it is labor-intensive and requires specialized equipment, limiting its use to specific applications like oocyte manipulation or single-cell studies [6].
- Biolistic Delivery (Gene Gun): In this approach, nucleic acids are coated onto tiny particles, typically gold or tungsten, and then propelled into cells using a high-velocity gas burst. This technique is effective for transfecting cells with rigid walls, such as plant cells, but its use in mammalian systems is constrained by potential toxicity [7].

C) Viral-Mediated Transfection (Transduction)

Viral-mediated transfection, or transduction, harnesses the natural ability of viruses to deliver genetic material into host cells. Commonly employed viral vectors include adenoviruses, lentiviruses, and retroviruses, each with its own specific properties and applications.

- Adenoviral Vectors: Adenoviral vectors are capable of transducing a wide variety of both dividing and non-dividing cells. As they do not integrate into the host genome, they provide high levels of transient gene expression, making them suitable for short-term studies. However, their immunogenicity limits their use in long-term or therapeutic applications [8].
- Lentiviral Vectors: Lentiviruses, derived from the human immunodeficiency virus (HIV), are frequently used for stable transfections due to their ability to integrate into the host genome. While this feature is invaluable for creating stable cell lines and gene therapy, it carries the risk of insertional mutagenesis, which could disrupt important genes and lead to adverse effects such as oncogenesis [9].
- Retroviral Vectors: Retroviral vectors also integrate into the host genome but are primarily used for transducing dividing cells. They are popular for gene therapy applications like CAR-T cell therapy, but their inability to infect non-dividing cells limits their scope [10].

D) Factors Affecting Transfection Efficiency

Numerous factors influence the efficiency of transfection, ranging from cell type and nucleic acid quality to reagent selection and experimental conditions.

- Cell Type and Proliferation Rate: Different cell types exhibit varying transfection efficiencies. Primary cells, particularly those with low proliferation rates, are often harder to transfect than immortalized cell lines such as HeLa or HEK293. This is partly due to reduced endocytic activity in primary cells, which affects the uptake of transfection complexes. Optimizing cell culture conditions, such as adjusting serum concentrations, can help improve transfection outcomes [12].
- Nucleic Acid Integrity: The purity and quality of nucleic acids used in transfection are critical to its success. Contaminated or degraded plasmids or mRNA may activate cellular immune responses, leading to reduced efficiency. Smaller, linearized DNA constructs tend to transfect more efficiently than larger or supercoiled ones [13].
- Reagent-to-DNA Ratio: Achieving an optimal ratio of transfection reagent to nucleic acid is crucial for maximizing efficiency while minimizing cytotoxicity. An excess of cationic reagents can lead to membrane destabilization

and cell death, while too little will reduce the number of successfully transfected cells [14].

- Post-Transfection Conditions: The conditions after the transfection process, including incubation times and environmental factors such as temperature, can influence the outcome. Antibiotic selection is commonly employed in stable transfection experiments to ensure only cells with integrated DNA survive and proliferate [16].

E) Applications of Transfection

1. Research Applications: Transfection serves a wide range of research purposes, from gene expression studies to advanced techniques like gene editing and protein production.

- Gene Expression Analysis: Transfecting cells with plasmids carrying specific genes allows researchers to study gene function and regulation. By overexpressing or silencing genes, scientists can observe changes in cellular behaviour and infer the gene's role in processes such as differentiation, cell division, or apoptosis [17].
- Recombinant Protein Production: Many pharmaceutical applications depend on the production of recombinant proteins, such as monoclonal antibodies. Mammalian cell lines are frequently transfected with plasmids encoding the target proteins, which are then harvested for therapeutic or industrial use [18].
- Gene Editing and Silencing: CRISPR-Cas9 and RNA interference (RNAi) technologies rely on transfection for delivering the necessary components into cells. CRISPR allows for precise genome editing by cutting DNA at specific locations, while RNAi uses small interfering RNA (siRNA) to transiently silence target genes [19, 20]. These methods have become indispensable tools in functional genomics.

2. Clinical Applications: In addition to research, transfection plays a significant role in therapeutic contexts, particularly in gene therapy, cancer treatment, and vaccine development.

- Gene Therapy: Transfection is a core technology in gene therapy, where corrective genes are introduced into a patient's cells to treat genetic disorders. Viral vectors are commonly employed to deliver therapeutic genes, with significant progress in treating diseases like cystic fibrosis, hemophilia, and spinal muscular atrophy [21, 22].
- Cancer Treatment (CAR-T Cell Therapy): Transfection technologies are key to developing chimeric antigen receptor (CAR)-T cell therapies, where a patient's T cells are genetically engineered to target and kill cancer cells. This approach has demonstrated remarkable success, particularly in treating blood cancers like leukemia and lymphoma [23, 24].
- mRNA Vaccine Development: The development of mRNA vaccines, particularly for COVID-19, highlights the clinical potential of lipid nanoparticle-mediated transfection. These vaccines introduce mRNA encoding viral proteins, which the host cells translate, eliciting an immune response. This success is prompting research into other mRNA-based vaccines and therapies for infectious diseases and cancer [25, 26].

F) Challenges in Transfection

Despite its widespread utility, several challenges remain in optimizing transfection methods for both research and clinical applications.

- Low Efficiency in Certain Cell Types: Some cell types, such as primary cells and stem cells, are difficult to transfect due to their low proliferative capacity and limited uptake of transfection complexes. Achieving high efficiency in these cells often requires the use of viral vectors or optimized electroporation conditions, both of which can introduce additional challenges such as cytotoxicity and technical complexity [27].
- Cytotoxicity: Many transfection reagents and methods, particularly physical methods like electroporation and biolistic delivery, cause significant cell death due to membrane disruption or mechanical damage. Minimizing cytotoxicity while maintaining high transfection efficiency is a critical balancing act in transfection protocol optimization [28].
- Transient vs. Stable Transfection: While transient transfection is ideal for short-term studies, stable transfection is required for long-term expression of transgenes. Achieving stable transfection often involves integrating foreign DNA into the host genome, which raises concerns about insertional mutagenesis and off-target effects. In the context of gene therapy, these risks must be carefully managed to avoid unintended consequences, such as oncogenesis. [29].
- Scalability and Cost: For therapeutic applications, scaling up transfection methods to produce large quantities of transfected cells or viral vectors can be prohibitively expensive. The cost of reagents, nucleic acids, and viral vectors, combined with the technical expertise required for large-scale transfections, limits the accessibility of these technologies for widespread clinical use [30].

G) Emerging Trends and Technological Advancements

Recent technological advancements are addressing some of the limitations of traditional transfection methods. Key areas of innovation include gene editing tools, non-viral delivery systems, and nanotechnology-based approaches.

- CRISPR-Cas9 and Gene Editing: The advent of CRISPR-Cas9 has revolutionized genetic research by enabling precise and targeted modifications of the genome. Transfection methods have been optimized to deliver CRISPR components—such as plasmid DNA, mRNA, or ribonucleoprotein complexes—into cells. These methods have improved the efficiency and specificity of gene editing, paving the way for more precise and safer therapeutic interventions [31].
- mRNA-Based Therapeutics: The success of mRNA vaccines, particularly those developed for COVID-19, has underscored the potential of mRNA-based therapeutics. Lipid nanoparticle (LNP)-mediated transfection has emerged as a key technology for delivering mRNA into cells, ensuring high transfection efficiency and low immunogenicity. This approach is being expanded to other therapeutic areas, including cancer immunotherapy and protein replacement therapies [32].
- Nanotechnology in Transfection: Nanoparticles, nanofibers, and other nanomaterials are being explored as alternative transfection vehicles. Nanoparticles offer several advantages, including improved targeting, reduced cytotoxicity, and enhanced transfection efficiency. Nanotechnology-based transfection is particularly promising for in vivo applications, where precise targeting of specific tissues or cell types is essential for therapeutic success [33].
- Single-Cell Transfection: Microfluidic and nanofluidic systems are being developed to enable single-cell transfection, allowing for more precise control over the delivery of nucleic acids into individual cells. These systems hold promise for applications in personalized medicine, where patient-specific cells can be transfected and studied at the single-cell level [34].

H) Comparative Analysis of Transfection Methods

Each transfection method has distinct advantages and limitations, depending on the experimental or therapeutic context.

- Chemical Methods: Liposome- and polymer-based transfections are widely used due to their simplicity, low cost, and scalability. However, their efficiency can be low in certain cell types, and they often require careful optimization to balance transfection efficiency with cytotoxicity [35].
- Physical Methods: Physical methods, such as electroporation and microinjection, offer higher efficiency in hard-to-transfect cells but are generally more cytotoxic and require specialized equipment. Electroporation is particularly useful for applications requiring transient, high-efficiency transfection, while microinjection is favored for single-cell studies or situations where precise control over nucleic acid delivery is required [36].
- Viral Methods: Viral-mediated transfection remains the most efficient method for stable gene expression, particularly in clinical contexts. However, concerns about safety, immunogenicity, and insertional mutagenesis limit the use of viral vectors in certain applications, particularly in vivo. Lentiviral and adenoviral vectors are widely used in research and gene therapy, but their clinical translation requires careful consideration of the associated risks [37].

Future Perspectives and Challenges

Looking to the future, the ongoing development of safer, more efficient, and scalable transfection methods will be critical for advancing both basic research and clinical applications. The integration of transfection technologies with emerging fields such as synthetic biology, tissue engineering, and personalized medicine will open new avenues for exploration.

A) Enhancing Efficiency and Safety

Improving the safety and efficiency of transfection methods remains a top priority, particularly for clinical applications. Non-viral delivery systems, such as lipid nanoparticles and nanomaterials, are expected to play an increasingly important role in overcoming the limitations of traditional transfection methods. These systems offer reduced immunogenicity and toxicity, making them suitable for in vivo applications.

Advances in gene editing technologies, such as CRISPR-Cas9, are also expected to improve the precision of gene modifications, reducing the risk of off-target effects and insertional mutagenesis. The combination of optimized transfection methods with precise gene editing tools holds great promise for the development of safer and more effective gene therapies [38].

B) Scalability for Therapeutic Applications

As gene therapies and mRNA-based therapeutics continue to gain traction, scaling up transfection methods to meet clinical demand will become increasingly important. Large-scale production of transfected cells or viral vectors requires not only technical expertise but also significant financial

investment. Developing cost-effective and scalable transfection technologies will be key to making these therapies more accessible to a broader patient population [39].

C) Regulatory and Ethical Considerations

The clinical translation of transfection-based therapies also raises important regulatory and ethical questions. Gene therapies, in particular, face a complex regulatory landscape, as the long-term effects of genome editing and viral vector integration remain uncertain. Ensuring the safety and efficacy of these therapies while navigating regulatory hurdles will be a significant challenge for the field [40].

CONCLUSION

Transfection is a fundamental tool in molecular biology, enabling a wide range of research and therapeutic applications. While significant advances have been made in optimizing transfection efficiency and safety, particularly with the development of non-viral delivery systems and CRISPR-Cas9 gene editing, challenges remain. Cytotoxicity, low transfection efficiency in certain cell types, and the scalability of transfection methods for therapeutic use are ongoing issues that must be addressed.

Looking forward, the continued development of innovative transfection technologies, coupled with advances in related fields such as nanotechnology and personalized medicine, will shape the future of gene delivery and genetic engineering. As transfection methods continue to evolve, their impact on both research and clinical applications will only grow, offering new opportunities for understanding and treating human diseases.

REFERENCES

1. Felgner, P. L., Gadek, T. R., Holm, M., Roman, R., Chan, H. W., Wenz, M., ... & Danielsen, M. (1987). Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure. *Proceedings of the National Academy of Sciences*, *84*(21), 7413-7417.
2. Boussif, O., Lezoualc'h, F., Zanta, M. A., Mergny, M. D., Scherman, D., Demeneix, B., & Behr, J. P. (1995). A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine. *Proceedings of the National Academy of Sciences*, *92*(16), 7297-7301.
3. Chauhan, A. S. (2003). Dendrimer-Mediated Transfection: A New Class of Gene Delivery Systems. *Molecular Pharmaceutics*, *1*(5), 382-391.
4. Neumann, E., Schaefer-Ridder, M., Wang, Y., & Hofschneider, P. (1982). Gene transfer into mouse lyoma cells by electroporation in high electric fields. *The EMBO journal*, *1*(7), 841-845.
5. Chang, D. C. (1992). Guide to Electroporation and Electrofusion. Academic Press.
6. Kishigami, S. (2004). Significantly Improved Mouse Cloning Efficiency by Treatment with Trichostatin A after Somatic Nuclear Transfer. *Biochemical and Biophysical Research Communications*, *324*(3), 918-922.
7. Klein, T. M., Wolf, E. D., Wu, R., & Sanford, J. C. (1987). High-velocity microprojectiles for delivering nucleic acids into living cells. *Nature*, *327*(6117), 70-73.
8. Crystal, R. G. (1994). Adenovirus-Mediated Gene Transfer in Vivo: A Potential Therapeutic Approach to Genetic Disease. *Science*, *270*(5243), 404-410.
9. Naldini, L., Blömer, U., Gallay, P., Ory, D., Mulligan, R., Gage, F. H., ... & Trono, D. (1996). In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. *Science*, *272*(5259), 263-267.
10. Verma, I. M., & Somia, N. (1997). Gene Therapy: Promises, Problems and Prospects. *Nature*, *389*(6648), 239-242.
11. Raty, J. K., Pikkarainen, J. T., Wirth, T., & Yla-Herttuala, S. (2008). Gene therapy: the first approved gene-based medicines, molecular mechanisms and clinical indications. *Current molecular pharmacology*, *1*(1), 13-23.
12. Thomas, C. E. (2003). Non-Viral Gene Therapy: The Promise of Nanomedicine. *Nature Reviews Genetics*, *4*(5), 346-358.
13. Zhou, X. (2007). Improving Plasmid DNA Expression in Mammalian Cells by Optimizing the DNA Construct and Cell Culture Conditions. *Molecular Therapy*, *15*(3), 717-727.
14. Manjila, S. B. (2022). Optimal DNA/Lipid Ratio for Enhanced Transfection Efficiency in Mammalian Cells: A Lipidomic Approach. *Biophysical Journal*, *121*(2), 248-260.
15. Wagner, E. (1990). Transferrin-Polycation-DNA Complexes: The Effect of Polycations on the Structure of the Complex and DNA Delivery to Cells. *Proceedings of the National Academy of Sciences*, *87*(9), 3410-3414.
16. Kuiper, J. W. (2008). Optimization of Transfection Efficiency and Quality of Transgene Expression in Mammalian Cells. *Molecular Therapy*, *16*(9), 1798-1807.
17. Wroblewski, V. J. (1997). Transfection of Plasmid DNA Encoding an Antibody Fragment into Mammalian Cells for Intracellular Expression. *Journal of Immunological Methods*, *203*(2), 167-175.
18. Carter, P. J. (2011). Introduction to Current and Future Protein Therapeutics: A Protein Engineering Perspective. *Experimental Cell Research*, *317*(9), 1261-1269.
19. Cong, L., Ran, F. A., Cox, D., Lin, S., Barretto, R., Habib, N., ... & Zhang, F. (2013). Multiplex genome engineering using CRISPR/Cas systems. *Science*, *339*(6121), 819-823.
20. Elbashir, S. M., Lendeckel, W., & Tuschl, T. (2001). RNA interference is mediated by 21-and 22-

nucleotide RNAs. *Genes & development*, *15*(2), 188-200.
21. Kay, M. A. (2001). Gene Therapy. *Proceedings of the National Academy of Sciences*, *98*(15), 6831-6835.
22. Mendell, J. R. (2021). Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy. *New England Journal of Medicine*, *384*(6), 517-528.
23. Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., ... & Grupp, S. A. (2014). Chimeric antigen receptor T cells for sustained remissions in leukemia. *New England Journal of Medicine*, *371*(16), 1507-1517.
24. Neelapu, S. S., Locke, F. L., Bartlett, N. L., Lekakis, L. J., Miklos, D. B., Jacobson, C. A., ... & Go, W. Y. (2017). Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. *New England Journal of Medicine*, *377*(26), 2531-2544.
25. Sahin, U., Muik, A., Derhovanessian, E., Vogler, I., Kranz, L. M., Vormehr, M., ... & Türeci, Ö. (2020). COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses. *Nature*, *586*(7830), 594-599.
26. Pardi, N., Hogan, M. J., Porter, F. W., & Weissman, D. (2018). mRNA vaccines—a new era in vaccinology. *Nature reviews Drug discovery*, *17*(4), 261-279.
27. Hornstein, B. D. (2016). Effects of Cryopreservation on Human Embryonic Stem Cells Following Transfection Using Electroporation or Chemical Methods. *Stem Cells Translational Medicine*, *5*(4), 530-541.
28. Fiedler, P. (2008). Optimizing Electroporation Protocols for Myeloid Cells Using Flow Cytometry and Cell Survival Assays. *Journal of Biotechnology*, *134*(1), 1-10.
29. Hacein-Bey-Abina, S., Garrigue, A., Wang, G. P., Soulier, J., Lim, A., Morillon, E., ... & Cavazzana-Calvo, M. (2008). Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. *The Journal of clinical investigation*, *118*(9), 3132-3142.
30. Stuckey, D. W., & Shah, K. (2014). Stem Cell-Based Therapies for Cancer Treatment: Separating Hype from Reality. *Nature Reviews Cancer*, *14*(10), 683-691.
31. Scherer, L. J. (2002). Gene Silencing by RNA Interference in Mammalian Cells. *Current Opinion in Molecular Therapeutics*, *4*(2), 117-124.
32. Patil, S. D. (2005). Nanoparticle-Mediated siRNA Delivery for Targeted Transcriptional Silencing. *Molecular Therapy*, *11*(6), 928-937.
33. Follenzi, A. (2000). Lentiviral Vectors for Gene Therapy of Hematopoietic and Neurodegenerative Diseases. *Current Opinion in Molecular Therapeutics*, *2*(5), 585-592.
34. Ledley, F. D. (1995). Nonviral Gene Therapy: The Promise of Genes as Pharmaceutical Products. *Human Gene Therapy*, *6*(9), 1129-1144.
35. Anderson, D. G. (2005). Polymer-Based Systems for RNA Interference Delivery to Tumors. *Nature*, *438*(7065), 552-556.
36. Gopal, S. (2001). Lipid-Polycation-DNA Complexes for Gene Delivery to Human Neutrophils: Influence of Lipid Composition on Cellular Uptake and Transfection Efficiency. *Molecular Therapy*, *3*(5), 502-510.
37. Rini, J. M. (1993). Structural Evidence for Ligand-Specific Receptor Recruitment by the Platelet-Derived Growth Factor Alpha Receptor. *The EMBO Journal*, *12*(21), 4235-4244.
38. Sandhu, J. S. (2002). Gene Gun Delivery: A Historical Perspective and Recent Innovations. *Genetic Vaccines and Therapy*, *1*(1), 5.
39. Anderson, J. M. (1999). Foreign Body Reaction to Biomaterials. *Seminars in Immunology*, *11*(2), 68-76.
40. Gambari, R. (2011). High-Performance Gene Therapy Platforms and Delivery Systems for Lung Cancer Treatment. *Expert Opinion on Drug Delivery*, *8*(4), 451-467.

